Lerodalcibep-liga
Brand names: Lerochol · Active ingredient: Lerodalcibep
In short: LEROCHOL® is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). Cardiovascular outcomes trials have demonstrated that reducing LDL-C lowers the risk for m
What is Lerodalcibep-liga used for?
LEROCHOL® is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH).
Cardiovascular outcomes trials have demonstrated that reducing LDL-C lowers the risk for major adverse cardiovascular events (MACE) in adults at increased risk when treated with statins or monoclonal antibody proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors as an add-on to statin therapy.
Lerodalcibep-liga dosage
The recommended dosage of LEROCHOL is 300 mg once monthly administered subcutaneously.
Assess LDL-C when clinically indicated. The LDL-lowering effect of LEROCHOL may be measured as early as 4 weeks after initiation and, provided monthly dosing is continued, anytime thereafter without regard to timing of the dose.
If a dose is missed by:
Less than 7 days, instruct the patient to administer LEROCHOL as soon as possible and resume the patient's original monthly dosage schedule.
Seven (7) or more days, instruct the patient to administer LEROCHOL as soon as possible and start a new monthly dosage schedule based on this date.
Train patients and/or their caregivers on how to prepare and administer LEROCHOL, according to the Instructions for Use, and instruct them to read and follow the Instructions for Use each time they use LEROCHOL.
Prior to use, allow LEROCHOL to warm to room temperature up to 25°C (77°F) for at least 30 minutes if LEROCHOL has been refrigerated .
Visually inspect LEROCHOL prior to administration. LEROCHOL is a clear to slightly opalescent, brownish-yellow to amber solution. Do not use if the solution is cloudy or contains particles.
Inject LEROCHOL subcutaneously into the abdomen or the upper front thighs. If injected by a healthcare provider or caregiver, the back of the upper arms can also be a site of injection . Do not inject in an area of the skin that is tender, bruised, red, or indurated. Rotate injection sites for each administration.
To administer the full 300 mg dose using the prefilled syringe, push plunger down until the syringe is empty before removing from the injection site.
To administer the full 300 mg dose using the autoinjector, continue to firmly hold the autoinjector down for 10 seconds after the second click, and check that the green plunger has stopped moving before removing from the injection site.
How to take Lerodalcibep-liga — instructions & advice from the label
Advise the patient and/or caregiver to read the FDA-Approved Patient Labeling (Patient Information and Instructions for Use).
Administration
Provide guidance to patients and caregivers on proper subcutaneous injection technique and how to use the prefilled syringe or the autoinjector correctly. Inform patients that the prefilled syringe or the autoinjector should be allowed to warm to room temperature for 30 minutes prior to use, if refrigerated .
Manufactured by: LIB Therapeutics, Inc.5375 Medpace WayCincinnati, OH 45227-1543U.S. License No. 2352
Version 0.6
Warnings & precautions
Do not take this medicine if: None.
Lerodalcibep-liga side effects
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Adverse Reactions in Adults with Primary Hypercholesterolemia
Adverse Reactions in Two Pooled 52-week Controlled Trials
In two pooled 52-week, double-blind, randomized, placebo-controlled trials (Trials 1 and 2), 1,229 patients received 300 mg of LEROCHOL subcutaneously every 4 weeks . The mean age was 64 years (range 25 to 90 years), 52% were 65 years of age or older, 37% female, 79% White, 18% Black or African American, 4% Asian; 7% identified as Hispanic or Latino ethnicity. At baseline, 9% of patients had a diagnosis of HeFH, 74% had established atherosclerotic cardiovascular disease (ASCVD), and 26% were at increased risk for ASCVD. Adverse reactions reported in at least 2% of LEROCHOL-treated patients and more frequently than in placebo-treated patients are shown in Table 1. Adverse reactions led to treatment discontinuation in 4% of LEROCHOL-treated patients and placebo-treated patients. The most frequent adverse reaction leading to treatment discontinuation was injection site reactions, with a higher frequency in the LEROCHOL-treated group compared to placebo-treated patients (1% vs. 0%). …
About this medicine
Lerodalcibep-liga is a recombinant fusion protein therapeutic agent comprised of a proprotein convertase subtilisin/kexin type 9 (PCSK9)-binding domain and human serum albumin (HSA). Lerodalcibep-liga is produced in genetically engineered mammalian (Chinese hamster ovary) cells as a single protein with an approximate molecular weight of 77 kDa.
LEROCHOL (lerodalcibep-liga) injection is a clear to slightly opalescent, brownish-yellow to amber, sterile, preservative-free solution for subcutaneous injection. Each single-dose prefilled syringe or single-dose autoinjector contains 1.2 mL of lerodalcibep-liga (300 mg), histidine (3.07 mg), L-histidine monohydrochloride (0.88 mg), polysorbate 80 (0.24 mg), sodium chloride (10.52 mg), and Water for Injection. The pH is 6.8.
How it works: Lerodalcibep-liga is a recombinant fusion protein that binds PCSK9 with picomolar affinity. PCSK9 binds to low-density lipoprotein receptor (LDLR) on the surface of hepatocytes to promote LDLR degradation within the liver. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 78c511a3-bc29-4e67-84b1-b966d1391cbf. Read the full official label on DailyMed.
Related medicines
Atorvastatin Amlodipine Lisinopril Losartan Metoprolol Rosuvastatin Simvastatin Spironolactone